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Abstract
Background: G-protein coupled receptors (GPR) bear the potential to serve as yet unidentified drug targets for psychiatric
and metabolic disorders. GPR12 is of major interest given its putative role in metabolic function and its unique brain
distribution, which suggests a role in emotionality and affect. We tested Gpr12 deficient mice in a series of metabolic and
behavioural tests and subjected them to a well-established high-fat diet feeding protocol.
Methodology/Principal Findings: Comparing the mutant mice with wild type littermates, no significant differences were
seen in body weight, fatness or weight gain induced by a high-fat diet. The Gpr12 mutant mice displayed a modest but
significant lowering of energy expenditure and a trend to lower food intake on a chow diet, but no other metabolic
parameters, including respiratory rate, were altered. No emotionality-related behaviours (assessed by light-dark box, tail
suspension, and open field tests) were affected by the Gpr12 gene mutation.
Conclusions/Significance: Studying metabolic and emotionality parameters in Gpr12 mutant mice did not reveal a major
phenotypic impact of the gene mutation. Compared to previous results showing a metabolic phenotype in Gpr12 mice with
a mixed 129 and C57Bl6 background, we suggest that a more pure C57Bl/6 background due to further backcrossing might
have reduced the phenotypic penetrance.
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Introduction
Mood and metabolic disorders are often closely linked. A
growing body of evidence shows that G-protein coupled receptors
(GPR) play central roles in neuronal control of body functions,
including psychiatric and metabolic disorders, and therefore
present as targets for drug intervention for either [1–4]. GPRs
comprise a large protein family of transmembrane receptors.
Following extracellular stimulation, cell-surface GPRs activate
intracellular signal transduction pathways that trigger important
events related to cell differentiation, proliferation, development
and survival [5]. Several GPRs have been de-orphanised in recent
years, including the G protein-coupled Receptor 12 (GPR12).
The Gpr12 gene was initially cloned from rat pituitary [6] and
later from human tissue [7]. It is expressed in several brain regions
by both neurons and microglia [8,9] as well as pituitary, ovary and
testis tissue, but absent in other tissues [6]. Sphingosine-1-
phosphate (S1p) [10], sphingosyl-phosphorylcholine (SPC) [11]
and more recently Tyrosol [12] were reported as high affinity
ligands for GPR12 amongst other GPRs. A phylogenetic tree
places GPR12 in close proximity to cannabinoid receptors [13,14];
of interest, because cannabinoid receptors are involved in
regulation of both emotionality and metabolism [15,16]. GPR12
was found to be highly abundant in the developing brain,
particularly in postmitotic neurons during cerebral cortical
development. Its occurrence shows a temporal pattern over
development and studies suggested a role of GPR12 in neuronal
differentiation, neuronal growth and the formation of synaptic
contacts [9,11]. It shows high similarity to GPR3 and GPR6, with
overlapping ligand spectrum, but different ligand affinity in
relation to differences in physiological function [11,17,18].
In adult mice, we and others found GPR12 in areas highly
relevant to both emotionality and metabolism, including the
cingulate cortex, hippocampus, habenular nucleus, nucleus
accumbens, piriform cortex, septum and amygdala [1,11]. In a
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previous study, we established a role of GPR12 in energy balance,
as Gpr12 gene deficiency resulted in increased weight gain,
decreased energy expenditure and dyslipidemia, with Gpr12
mutant mice showing symptoms of obesity [1].
In this study, we aimed to further examine the role of GPR12 in
metabolic function, establish its influence on emotionality and
relate our findings to plasma hormones which have been shown to
have roles in both emotionality and metabolism [19]. Further, we
explored a potential impact of various genetic backgrounds on the
phenotype of a Gpr12 mutation, which was originally introduced
in a mixed C57Bl/6 and 129/OlaHsd genetic background [1]. For
this, we tested Gpr12 mutant mice that were further backcrossed
into C57Bl/6 backgrounds from disparate animal providers
compared to mice from our initial studies [1]. Animals were
subject to a series of metabolic and behavioural tests as well as to a
well established protocol of high-fat diet (HFD) feeding [20]. In
line with previous results we found a modest effect of a Gpr12
deficiency on lowered energy expenditure. There was, however,
no significant difference in body weight gain or composition, either
under chow or HFD conditions, and no impact of a Gpr12
deficiency on the animals’ emotionality. Our data indicate a
potential influence of the C57Bl/6 background with present results
partially contrasting our previous findings in an earlier generation
of Gpr12 deficient mice [1].
Results
Analysis of Gpr12 Mutant Mice Backcrossed for 6
Generations in C57Bl/6JOlaHsd – Swedish Studies
Metabolic parameters. Body weight at any measured time
point (Figure 1) and body composition (Table 1) did not
significantly differ between Gpr12 deficient (Gpr12 KO) and
wildtype (WT) mice. In line with this, no significant differences
were observed for absolute or relative body fat mass, body lean
mass, bone mineral density or bone mineral content between
Gpr12 KO and WT mice. Moreover, neither absolute nor relative
(relative to body weight) energy intake was significantly different
between the groups of mice (Table 1) when assessed by a fasting/
refeeding study protocol.
Gpr12 KO mice displayed, however, a significantly lower
energy expenditure compared to WT mice (Figure 2A), but
without a corresponding reduction of either core body tempera-
ture (Table 1) or locomotor activity (see behavioural tests below).
Respiratory exchange ratio (Figure 2B) was not significantly
different between Gpr12 KO and WT mice, indicating a similar
energy source. Food intake showed a slight trend to be lower in
Gpr12 KO mice when assessed simultaneously with energy
expenditure (Figure 2C).
Core body temperature recorded at room temperature was not
significantly different between Gpr12 KO and WT mice. Also
when KO and WT mice were subjected to a 5uC ambient
temperature for 45 minutes, no significant difference in core body
temperature and therefore thermogenesis was observed (Table 1).
In the oral glucose tolerance test, no significant differences were
observed in fasting blood glucose or blood glucose response to the
orally administered glucose between Gpr12 KO and WT mice.
Fasting insulin levels were, however, significantly higher (Table 2),
whereas the insulin response to the glucose administration was not
significantly different between Gpr12 KO and WT mice (data not
shown).
No significant differences were observed for blood plasma levels
of triglycerides, total cholesterol, nonesterified fatty acids, leptin or
adiponectin between Gpr12 KO and WT mice at 20 weeks of age.
In liver biopsies hepatic triglyceride content was not significantly
different between Gpr12 KO and WT mice (Table 2).
Behavioural Tests
No significant differences between Gpr12 KO and WT mice
were observed for any parameter in the open field locomotor
activity analysis on either of the two test days (Table 3), including
no significant differences in faecal pellet production during the
experimental time (Table 3), indicating unaltered emotionality
[21].
Figure 1. Body weight gain on lab chow. Body weight
development in Gpr12 knockout (KO; n = 8) mice (red line) and wildtype
(WT; n = 8) mice (dotted line) showed no difference at any measured
time point.
doi:10.1371/journal.pone.0042395.g001
Table 1. Body composition, food intake and body
temperature of wild type (WT) and Gpr12 deficient (Gpr12 KO)
mutant mice – Swedish study.
WT Gpr12 KO
Body composition
Bone mineral density (mg/cm2) 43.6160.37 43.1960.44
Bone mineral content (g) 0.4060.01 0.3960.01
Rel. bone mineral content (mg/cm) 39.4260.62 38.6960.75
Body lean mass (g) 19.0560.28 18.8160.49
Rel. body lean mass (g/cm) 1.8960.02 1.8760.04
Body fat mass (g) 2.9160.13 2.8060.15
Rel. body fat mass (% of bw) 13.2460.60 12.8860.50
Food intake
Absolute food intake (g/day) 7.5860.36 7.9460.21
Relative food intake (g/g bw) 0.3360.02 0.3460.01
Absolute energy intake (kcal/day) 23.361.11 24.560.65
Relative energy intake (kcal/g bw) 1.0260.06 1.0560.03
Core rectal body temperature
Core temp. at room temp. 37.1960.19 37.1460.17
Core temp. at 5uC ambient temp. 37.5160.13 37.2860.15
n = 8 per group; bw Body weight
doi:10.1371/journal.pone.0042395.t001
Metabolism and Emotionality in Gpr12 Mutant Mice
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Analysis of Gpr12 Mutant Mice re-derived in C57Bl/6ARC
Mice – Australian Studies
Metabolic parameters. While fed with normal lab chow, no
differences in body weight were found at 13 weeks or 18 weeks of
age between Gpr12 KO and WT mice, despite a trend to higher
weight in the Gpr12 KO group (Figure 3).
After onset of high-fat diet (HFD) feeding at 13 weeks of age,
animals of all groups strongly increased their weight gain (p,0.01).
There was, however, no significant interaction of weight increase
over time and the respective genotypes, with also no difference in
body weight at any time point between week 1 and week 7 of HFD
feeding between Gpr12 KO and WT mice. When fasted
overnight, all animals showed a significant weight loss (p,0.05),
which was, however, not different between Gpr12 KO and WT
mice.
Fasting levels of glucose, leptin and insulin did not differ
between Gpr12 KO and WT mice (Table 4).
Behavioural Tests
For all behavioural parameters (Table 5), no significant
differences between Gpr12 KO and WT animals were found,
which included anxiety-related behaviours in the dark-light and
open field test, depression-like parameters in the tail suspension
test as well as locomotor activity in the dark-light box and open
field test.
Heterozygous Gpr12 mice (n = 15) were subjects to the
behavioural testing at the same time as Gpr12 KO and WT mice
in order to determine if a reduction, rather than complete
abrogation, of Gpr12 might have exposed a more subtle
phenotypic effect. No differences between heterozygous Gpr12
Figure 2. Energy expenditure. (A) Relative energy expenditure (EE),
(B) respiratory exchange rate (RER) and (C) relative food intake (FI) of
Gpr12 knockout (KO; n = 8) mice (red line) and wildtype (WT; n = 8) mice
(dotted line). Whereas EE was significantly different between Gor12 KO
and WT, RER and FI did not differ (2-way ANOVA with factors time and
genotype; **p,0.01).
doi:10.1371/journal.pone.0042395.g002
Table 2. Blood chemistry and hepatic lipids of wild type (WT)
and Gpr12 deficient (Gpr12 KO) mutant mice – Swedish study.
WT Gpr12 KO
Levels after 5h fasting
Glucose (mM) 10.1260.34 10.2760.33
Plasma Insulin (ng/ml) 0.6460.06 1.4960.32*
n = 6 per group; *p,0.05
Plasma chemistry
Cholesterol (mM) 2.8660.05 2.7060.10
Triglyceride (mM) 0.9060.05 1.0360.11
NEFA (mM) 0.5760.02 0.6260.06
Leptin (ng/ml) 8.8061.79 6.2961.20
Adiponectin (nM) 165.4613.5 152.8617.2
Hepatic lipid content
Hepatic lipid content (mg/g) 22.5162.07 17.8662.85
n = 8 per group; NEFA nonesterified fatty
acids
doi:10.1371/journal.pone.0042395.t002
Table 3. Emotionality parameters of wild type (WT) and
Gpr12 deficient (Gpr12 KO) mutant mice – Swedish study.
WT Gpr12 KO
Behavioural parameters
- Open Field Test (day1)
Ambulatory activity (beam breaks) 3648.66126.6 4198.66470.6
Faecal pellets (n) 6.060.9 5.960.6
- Open Field Test (day2)
Ambulatory activity (beam breaks) 2805.46212.6 2769.56342.4
Faecal pellets (n) 5.160.8 6.861.0
n = 8 per group
doi:10.1371/journal.pone.0042395.t003
Metabolism and Emotionality in Gpr12 Mutant Mice
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mutant mice and either their Gpr12 KO or WT littermates were
observed (Major test parameter results for heterozygous KO
animals (see Table 5 for Gpr12 KO and WT results): Dark-Light
Box, time spent in light (s): 206.2611.7; Tail suspension test, time
immobile (s): 18665.1; Open Field test, distance moved (cm):
106896274).
Discussion
In this study, we examined the effects of a mutation in the G
protein-coupled receptor 12 (Gpr12) gene on metabolic and
emotionality parameters. With Gpr12 expression found in several
brain areas highly relevant for emotionality [1,9], we hypothesised
that the Gpr12 gene might synergistically influence emotionality
and metabolism. Studying Gpr12 deficient compared to wild type
(WT) littermates from two different populations, we could,
however, not detect any major differences in the studied metabolic
parameters or emotionality-related behaviours.
In reporter cell lines, GPR12 was stated to constitutively
activate both Gs and Gq pathways [22]. GPR12 stimulation can
therefore positively regulate adenylyl cyclase to catalyse ATP to
cAMP and further activate Protein kinase A. At the same time, it
can activate phospholipase C to hydrolyse phosphatidylinositol
bisphosphate to produce inositol trisphosphate (IP3) and diacyl-
glycerol (DAG). Whereas IP3 will facilitate the release of calcium
from intracellular stores, DAG recruits protein kinase C (PKC)
and induces downstream phosphorylation [5]. Whereas both
intracellular pathways have been shown to be critically involved in
emotionality as well as in metabolic function, GPR12 has to date
only been shown to significantly influence cAMP levels as required
for meiotic arrest. We previously reported Gpr12 expression in
areas highly relevant to both emotionality and metabolism,
including the cingulated cortex, hippocampus, habenular nucleus,
nucleus accumbens, piriform cortex, septum and amygdala [1,11].
Whatever its function in these areas is, GPR12 does not appear to
influence aspects of emotionality tested using the currently
accepted techniques nor overall energy balance when on a more
‘pure’ C57/Bl6 background. Equally, our results are perhaps even
more surprising given that GPR12 has been found to be highly
abundant in the developing brain, particularly influencing
neuronal differentiation [9,11], based on which we expected a
mutation in its gene to induce both metabolic and behavioural
deficits.
Metabolic Parameters
We have previously reported an early onset of increased weight
gain, lower energy expenditure and increased body fat mass in
Gpr12 mutant mice fed a normal chow diet and backcrossed for 4
generations towards C57Bl/6JOlaHsd [1]. Given the multiple
examples of phenotype sensitivity of knockout mice from different
sources [23,24], we investigated potential influences of the Gpr12
mutation by varying genetic backgrounds with a new assessment
set up in chow fed Gpr12 deficient mice backcrossed for 6
generations towards C57Bl/6JOlaHsd. In our previous study, we
could show that a Gpr12 deficiency resulted in dyslipidemia and
signs of obesity as a result of changed energy homeostasis. A
significantly higher body weight was observed for Gpr12 deficient
mice at both 5 and 11 weeks of age compared to WT mice, which
was attributed to a decreased energy expenditure of the Gpr12
mutant mice [1]. In the present study when backcrossed only two
to four more generations onto C57Bl/6 genetic background, we
could not reproduce our previous findings of increased body
weight gain or composition in Gpr12 deficient mutant when fed
normal lab chow in either of the studied populations (Figures 1
and 3; Table 1). Backcrossing of our animals from the previously
studied 4th generation [1] to the 6th generation in the presented
Swedish studies increased the C57Bl6 background from 93.8% to
98.4%. Previous studies have shown that, likely due to epistatic
Figure 3. Body weight gain on high-fat diet. Body weight
development in Gpr12 knockout (KO; n = 8) mice (red line) and wildtype
(WT; n = 8) mice (dotted line) fed with lab chow, high-fat diet or after
fasting showed no difference at any measured time point.
doi:10.1371/journal.pone.0042395.g003
Table 4. Blood chemistry of wild type (WT) and Gpr12
deficient (Gpr12 KO) mutant mice – Australian study.
WT Gpr12 KO
Levels after overnight fasting
Plasma Insulin (pg/ml) 42.4621.3 38.5611.2
Plasma Leptin (pg/ml) 270.7669.8 318.66116.5
Glucose (mM) 6.560.4 6.260.5
n = 7 for WT and n = 15 for Gpr12 KO
doi:10.1371/journal.pone.0042395.t004
Table 5. Emotionality parameters of wild type (WT) and
Gpr12 deficient (Gpr12 KO) mutant mice – Australian study.
Behavioural parameters
- Dark-Light Box
Time spent in light (s) 224.1614.3 234.1620.9
Distance moved (cm) 27736153 24906162
- Tail suspension Test
Time immobile (s) 178.9619.1 174.5616.6
Latency immobility (s) 54.167.3 49.865.2
- Open Field Test
Distance moved (cm) 101666686 108096414
Latency to inner zone (s) 34612.6 4167.2
Frequency inner zone (n) 63.266 54.766.9
n = 5 per group
doi:10.1371/journal.pone.0042395.t005
Metabolism and Emotionality in Gpr12 Mutant Mice
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interactions with the respective strain background, even small
variation in purity can affect phenotypic penetrance [25]. We also
tested heterozygous Gpr12 mutant mice (n = 12–15) to identify
potential differences of reduction vs total ablation of GPR12 (data
shown only for behavioural parameters). With no difference
compared to either homozygous mutant or WT mice, this
possibility was ruled out. The only difference, as observed
previously [1] was modestly reduced energy expenditure in
Gpr12 deficient mice (Figure 2A). The lack of effect on overall
weight gain or body fat could not be explained by any overt
differences in respiratory exchange rate (Figure 2B), body
temperature at different ambient temperatures, or locomotor
activity (Table 3). The trend towards slightly decreased food intake
of Gpr12 KO mice (Figure 2C) as also observed previously [1]
might account for why the reduced energy expenditure did not
yield differences in weight gain. More subtle but relevant changes
in these and other metabolic parameters cannot be ruled out.
To further investigate the potential impact of GPR12 on
metabolism, we exposed Gpr12 KO and WT mice to a well
established high-fat diet protocol (for composition see Table 6)
[20,26]. As with the outcomes on normal lab chow, we could not
find any difference in body weight gain due to the genotype
(Figure 3). We found, as previously reported, several diet resistant
mice, which was, however, also independent of their genotype
(data not shown). Body weight loss due to overnight fasting was
also unaffected by the Gpr12 mutation. While fasting insulin levels
were significantly higher in generation 6 C57Bl/6JOlaHsd
backcrossed animals, they did not differ in re-derived C57Bl/
6ARC mice, indicating possibly a subtle impact of the respective
C57Bl/6 background. There were no other effects of genotype on
other metabolic variables.
Emotionality-related Behaviour
In previous studies, GPR12 was demonstrated to be localised in
areas highly involved in emotionality regulation and related
behaviours, including the cingulate cortex, hippocampus and
amygdala [1,11]. The Gpr12 gene was found expressed in both
neurons and microglia and involved in neurodevelopment [8,9].
This indicated that deficits in GPR12 and its signalling,
particularly during development as in mutant animals, could
contribute to the development of psychopathologically relevant
behaviours.
Genetic approaches in the form of targeted gene mutations have
been used to study the pathophysiological impact of genetic loci on
emotionality-related behavioural and neurochemical parameters
to further understand the genetic basis of mood and metabolic
disorders [27,28]. Therefore, by conducting a series of behavioural
tests specifically designed to examine anxiety-related and depres-
sion-like behaviour as well as locomotion, it was deemed to be
possible to infer the role of a Gpr12 gene dysregulation in Gpr12
mutant mice.
When studying emotionality-related parameters in both the
Swedish or Australian cohort of mice, we could not find any
evidence for differences between Gpr12 mutant and WT mice.
Considering that a reduction, rather than complete abrogation, of
Gpr12 might reveal a phenotypic effect we also studied
heterozygous Gpr12 mutant mice. In a preliminary study,
heterozygous Gpr12 mutant mice exhibited trends towards
increased depression-like behaviour in the tail suspension test
(Piyaratna, unpublished). The tail suspension test has previously
been shown to be relevant to uncover behavioural despair in
genetically modified mice, with genetically engineered mice
modelling psychopathologies exhibiting greater behavioural de-
spair [27,29]. However, despite testing a large number of
heterozygous mutant mice (n = 15), no behavioural differences
were seen in comparison to either Gpr12 KO or WT mice.
Although the relatively small sample size in the Australian study is
to be noted, its results are confirmed by the behavioural tests
performed in the Swedish study as well as the results from
heterozygous Gpr12 mutant mice,
With the important role of Gpr12 in early neurodevelopment
and its distribution in both energy balance and emotionality
relevant brain areas [1,11], the totality of the present results is
unexpected. Considering the high homology and overlapping
ligand spectrum of GPR12 with other GPRs [11,17,18], compen-
satory responses, particularly of the highly homologous GPR3 and
GPR6, remain as a potential explanation for the lack of effect of a
Gpr12 mutation. Lack of expression data for these GPRs is a
limitation of our studies.
Given our earlier more positive results [1] on 4 generation
backcrossed mice, the current lack of differences may indicate a
delicate interaction between the Gpr12 gene and other genes in
the 129 compared to the C57Bl/6 genome. The importance of the
genetic background into which a gene-targeted allele is introduced
has previously been discussed to have the potential to influence the
resulting phenotypes as well as their penetrance [24,30]. Partic-
ularly for 129 and C57Bl/6 backgrounds, several studies have
shown that the penetrance of phenotypic and hormonal charac-
teristics of various gene deficiencies are dependant on the hosting
mouse strains [24,31–33]. Indeed, depending on the genetic
background, the Gpr12 gene expression might be deviating from
our previously reported pattern [1], and therefore potentially
account for the relative penetrance of characteristics of a Gpr12
mutation in varying C57Bl/6 backgrounds.
Altogether, although we found a deficiency in energy expendi-
ture in line with previous results, there was no effect of a Gpr12
mutation on any other metabolic and emotionality-related
behavioural parameter studied. Considering its unique distribution
in the brain and its involvement in neuronal differentiation
[1,9,11], further studies accounting for the genetic backgrounds
should address potential compensatory effects and the further
potential of GPR12 as a drug target for psychopathology and
metabolic disorders.
Table 6. High-fat diet composition – Australian study.
Ingredient % Weight % Energy/Kcal
Total Carbohydrate 50 46
Cornstarch 44
Sucrose 6
Total Fat 19 38
Lard 15
Sunflower oil 4
Total Protein 18 16
Gelatine 5
Casein 13
Total others 13 0
Fiber 5
Minerals 7
Vitamins 1
Energy Density (ED) Kcal/g: 3.78
doi:10.1371/journal.pone.0042395.t006
Metabolism and Emotionality in Gpr12 Mutant Mice
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Materials and Methods
Studies were carried out at AstraZeneca R&D Mölndal,
Sweden, and the University of Wollongong, Australia, as
indicated.
Ethics Statement
All procedures involving experimental mice were performed in
accordance with protocols approved by the local Animal Ethics
Committee at the University of Gothenburg under the European
Communities Council Directive and the Animal Ethics committee
of the University of Wollongong under the Australian Code of
Practice for the Care and Use of Animals for Scientific Purposes.
All steps were taken to ameliorate suffering in all work involving
our study animals, including regular health checks during housing
and optimised, least impact experimental procedures as approved
by the local ethics committees.
Gpr12 Mutant Mice Backcrossed for 6 Generations in
C57Bl/6JOlaHsd (Sweden)
Gpr12 mutant mice were obtained from Deltagen (San Carlos,
USA) as described previously [1]. In Sweden, the mouse line was
backcrossed for 6 generations on the C57bl/6JOlaHsd (Harlan,
the Netherlands) inbred mouse strain before heterozygous
intercross was performed to generate homozygous Gpr12 mutants
(Gpr12 KO) and wild type litter mates (WT).
Male Gpr12 KO mice (n = 8) and WT littermates (n = 8) were
subjected to a series of metabolic analyses and open field testing, as
described below and previously [34], to understand how further
backcrossing affects metabolic and behavioural phenotypes.
Gpr12 Mutant Mice Re-derived in C57Bl/6ARC Mice
(Australia)
Blastocytes of Gpr12 mutant mice backcrossed to C57Bl/
6JOlaHsd for 8 generations were obtained and re-derived in
C57Bl/6ARC (ARC, Australia) mice, and further backcrossed
into C57Bl/6ARC for 4 generations at the animal facilities of
the University of Wollongong, Australia, before creating
homozygous Gpr12 mutants (Gpr12 KO), heterozygous Gpr12
mutants and wild type litter mates (WT) from a heterozygous
intercross. Two separate sets of animals were used for the
following experiments. Animals of the first set were fed a high-
fat diet for 7 weeks commencing at the age of 18 weeks (Gpr12
KO n = 15, WT n = 7). The second set of animals was fed with
lab chow ad libitum only and behavioural testing was
performed as described below (Gpr12 KO n = 5, WT n = 5).
Heterozygous Gpr12 animals (n = 12–15) have been included in
the respective studies and tested at the same time, but with no
difference to either homozygous or wildtype animals, data is
only partially presented.
Housing
At either facility, mice were housed under standard conditions
(food and water ad libitum; 2262uC; 12:12 hour light-dark cycle).
At the age of 4 weeks, mice were weaned and ear marked.
Genotyping was performed using PCR on obtained ear tissue. For
the Gpr12 gene, one primer was located upstream of the deleted
region in the short arm (50-CT GTCTTTCCGTTGAAGAG-
GACAGG-30), a second primer located in exon 2 (50-TCACAG-
CAGATGAGGGTTCCTGAGC-30) and the third located in the
targeting cassette (50-TTCAACAGACCTTG-
CATTCCTTTGG-30) [1].
Metabolic Analyses (Sweden)
Body weight was recorded in chow (R3, Lactamin, Stockholm,
Sweden) fed mice weekly from 4–8 weeks of age and then at 16
and 20 weeks of age. Body composition at 8 weeks of age was
assessed by dual energy X-ray absorptiometry (DEXA) as
previously described [34]. The mice were assessed at age 7 weeks
in the comprehensive laboratory animal monitoring system
(CLAMS, Columbus Instruments, Columbus, USA) over 48
consecutive hours at room temperature as described previously
[34]. Food intake was assessed at 11 weeks of age over 48 hours by
a fasting/re-feeding model, with 12 hour over-night fasting prior
to experiment start as previously described [35]. Open field
locomotor activity analysis was performed on two consecutive days
at 8 weeks of age as described previously [34]. Core body
temperature was recorded by a rectal probe, both at room
temperature and also after exposure to a 5uC ambient temperature
for 45 minutes. Fasting blood glucose, insulin and oral glucose
tolerance was analysed in 5 hr diet deprived Gpr12 KO and WT
mice at 12 weeks of age. Blood samples were collected from the
tail vein before and 15, 30, 60, 90 and 120 minutes after oral
glucose administration (2g/kg bw) to assess blood glucose (Accu-
Chek, Roche Diagnostics, Manheim, Germany) and insulin
(Crystal Chem, Downers Grove, USA).
Blood samples were taken at 20 weeks of age by cardiac
puncture from isoflurane sedated non-fasted mice in EDTA coated
tubes and plasma was separated by centrifugation and snap frozen
in liquid nitrogen and subsequently stored in 280uC. Plasma levels
of cholesterol, triglycerides, nonesterified fatty acids, leptin and
adiponectin was assessed by commercial kit used previously by our
group [36]. The liver was dissected, weight and hepatic
triglyceride content determined as described previously [36].
High-fat Diet (HFD) Feeding (Australia)
Body weight of all animals was measured at the age of 13 weeks
and 18 weeks with animals being fed lab chow (Y.S. Feeds Pty
Ltd., Young, Australia). Thereafter, animals were weighed weekly
during HFD feeding as well as before and after fasting. Beginning
with the age of 18 weeks, animals were fed with HFD (see Table 6
for diet composition) ad libitum for 7 weeks. After 7 weeks of HFD
feeding, all animals were fasted overnight (no access to food; access
to water ad libitum) and euthanised the next morning to measure
fasting hormone plasma levels. Blood glucose was measured from
a drop of tail blood using a Glucotrend Instrument (Roche,
Germany) as reported previously [26]. Trunk blood was sampled
in EDTA-coated tubes, supplemented with Aprotinin and
centrifuged for 10 min at 4uC. Plasma was stored at 280uC until
further analysis. Leptin and Insulin levels were measured using a
2-plex Luminex assay (Millipore, USA) on a LUMINEX 100
following the manufacturer’s instructions.
Behavioural Tests (Sweden)
Assessment of open field locomotor activity was performed on
two consecutive days to investigate exploratory behaviours in a
novel environment as well as typical locomotor behaviours, and
included recordings of horizontal activity, peripheral vs. central
activity, rearing assessments and corner time, as previously
described [34]. In short, the mice were placed in the centre of
an open field (50650 cm) at the start of the experiment and
locomotor behaviours were assessed by recordings of beam breaks
by infrared sensors over 60 min. After the experiment, the mice
were removed to their home cages and the number of faecal boli
produced over 60 min were noted.
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Behavioural Tests (Australia)
Behavioural testing commenced at the age of 8 weeks with all
animals having only received lab chow ad libitum. All behavioural
tests were carried out between 8am and 12pm on each testing day,
with a two day test-interval. The recordings were analysed by an
observer blind to the genotype using Ethovision (Noldus, Nether-
lands).
Dark-Light box (DaLi). The DaLi box is an ethologically
relevant approach-avoidance conflict test for anxiety-related
behaviour, which is based on the natural conflict between the
tendency of mice to explore a novel area and avoid brightly lit
aversive areas [37,38]. The test arena consisted of a dark black
(15625 cm, 5lux) and a bright white (25625, 80lux) compartment,
connected by a 565 cm gate. The apparatus was cleaned before
each test session with water containing a detergent. The animal
was placed into the dark compartment and could freely explore
the arena for 10 min. Recorded behaviour was analysed using
Ethovision. Time spent in the bright white area was used as an
index for anxiety. The total locomotion in each compartment was
assessed as locomotion parameter.
Tail suspension test (TST). The TST belongs to the most
widely used models for assessing depression-like behaviour in
ethological, pharmacological and genetic mouse models [39,40].
For the TST, animals were attached with scotch tape on the tail to
the tail suspension device at a height of 30 cm, where they
remained for 6 min as described previously [40]. The animal’s
behaviour was videotaped and analysed by a trained observer
blind to the genotype using Eventlog. The duration of and latency
to immobility were taken as index of depression-like behaviour.
Open field test (OF). Spontaneous and drug induced
hyperlocomotion in the open field is used to study schizophre-
nia-related hyperactivity [41,42]. Animals were exposed to a
round open field arena (40 cm diameter, 20lx). The arena was
cleaned with water containing a detergent before every animal.
Animals were exposed for 30 min to the arena. Total distance
travelled and time in the inner zone (16 cm diameter) were
analysed using Ethovision.
Statistical Analyses
Statistical analyses were performed using SPSS (version 17.0,
SPSS Inc., Chicago, USA). The Kolmogorov-Smirnov test was
used to analyse data for normal distribution. All data were found
to be normally distributed. Repeated ANOVA was performed for
repeated measures with the factors time and genotype. Indepen-
dent groups were compared using a Student T-test. All data is
expressed as means 6 standard error of the mean (SEM), with
significance accepted at p,0.05.
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